Table 1.
Sample characteristics for all patient groups, standard stratification, and re-stratified by MM/ITC status
| Parameters | Total (N = 87) | Standard stratification (SS) group | Re-stratification (RS) group | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Stage I/II (SS1a) (N = 57) | Stage III (SS2b) (N = 30) | p-value1 | RS16 (N = 38) | RS27 (N = 19) | RS38 (N = 24) | RS49 (N = 6) | p-value5 | ||
| Sex, male, n (%) | 39 (44.8) | 24 (42.1) | 15 (50.0) | 0.4822 | 18 (47.4) | 6 (31.6) | 13 (54.2) | 2 (33.3) | 0.4552 |
| Age, years, mean (SD) | 68.4 (9.9) | 68.0 (9.9) | 69.2 (9.9) | 0.5723 | 69.7 (9.4) | 64.5 (10.4) | 69.4 (10.2) | 68.5 (9.4) | 0.27310 |
| Male | 68.7 (9.6) | 68.3 (10.4) | 69.5 (8.3) | 0.7043 | 69.8 (10.2) | 63.7 (10.5) | 68.2 (7.9) | 78.0 (7.1) | 0.28710 |
| Female | 68.2 (10.2) | 67.8 (9.7) | 69.0 (11.5) | 0.7013 | 69.7 (8.8) | 64.9 (10.8) | 70.9 (12.6) | 63.8 (6.3) | 0.35310 |
| T stage, n (%) | |||||||||
| T1 | 2 (2.3) | 1 (1.8) | 1 (3.3) | 0.6732 | 1 (2.6) | 0 | 1 (4.2) | 0 | NA4 |
| T2 | 10 (11.5) | 8 (14.0) | 2 (6.7) | 7 (18.4) | 1 (5.3) | 2 (8.3) | 0 | ||
| T3 | 66 (75.9) | 43 (75.4) | 23 (76.6) | 28 (73.7) | 15 (78.9) | 18 (75.0) | 5 (83.3) | ||
| T4 | 9 (10.3) | 5 (8.8) | 4 (13.3) | 2 (5.3) | 3 (15.8) | 3 (12.5) | 1 (16.7) | ||
| N stage, n (%) | NA4 | ||||||||
| N0 | 57 (65.5) | 57 (100) | 0 | 38 (100) | 19 (100) | 0 | 0 | NA4 | |
| N1 | 18 (20.7) | 0 | 18 (60.0) | 0 | 0 | 17 (70.8) | 1 (16.7) | ||
| N2 | 12 (13.8) | 0 | 12 (40.0) | 0.1662 | 0 | 0 | 7 (29.2) | 5 (83.3) | |
| Tumor differentiation, n (%) | |||||||||
| High | 18 (20.7) | 14 (24.6) | 4 (13.3) | 9 (23.7) | 5 (26.3) | 4 (16.7) | 0 | 0.3122 | |
| Moderate | 54 (62.1) | 36 (63.1) | 18 (60.0) | 0.4823 | 25 (65.8) | 11 (57.9) | 15 (62.5) | 3 (50.0) | |
| Low | 15 (17.2) | 7 (12.3) | 8 (26.7) | 4 (10.5) | 3 (15.8) | 5 (20.8) | 3 (50.0) | ||
| Lymph nodes, mean (SD) | 40.7 (18.4) | 39.7 (16.5) | 42.7 (21.8) | 41.8 (18.4) | 35.6 (11.2) | 45.1 (23.1) | 32.8 (12.8) | 0.2603 | |
| Location recurrence, n (%) | NA4 | ||||||||
| No metastasis, n (%) | 71 (81.6) | 49 (86.0) | 22 (73.3) | 35 (92.1) | 14 (73.7) | 19 (79.2) | 3 (50.0) | NA4 | |
| Liver | 5 (5.7) | 2 (3.5) | 3 (10.0) | 0 | 2 (10.5) | 3 (12.5) | 0 | ||
| Lung | 2 (2.3) | 1 (1.8) | 1 (3.3) | 0 | 1 (5.3) | 0 | 1 (16.7) | ||
| Local | 3 (3.4) | 0 | 3 (10.0) | 0 | 0 | 1 (4.2) | 2 (33.3)- | ||
| Other locations | 1 (1.1) | 1 (1.8) | 0 | 0 | 1 (5.3) | 0 | 0 | ||
| New cancer | 5 (5.7) | 4 (7.0) | 1 (3.3) | 3 (7.9) | 1 (5.3) | 1 (4.2) | 0 | ||
| Tumor location, n (%) | 0.3032 | ||||||||
| Coecum | 38 (43.7) | 25 (43.9) | 13 (43.3) | 14 (36.8) | 11 (57.9) | 10 (41.7) | 3 (50.0) | 0.2142 | |
| Ascending | 31 (35.6) | 21 (36.8) | 10 (33.3) | 16 (42.1) | 5 (26.3) | 10 (41.7) | 0 | ||
| Right flexure | 10 (11.5) | 6 (10.5) | 4 (13.3) | 5 (13.2) | 1 (5.3) | 3 (12.5) | 1 (16.7) | ||
| Transversum | 6 (6.9) | 5 (8.8) | 1 (3.3) | 3 (7.9) | 2 (10.5) | 0 | 1 (16.7) | ||
| Synchronous cancer | 2 (2.3) | 0 | 2 (6.7) | 0 | 0 | 1 (4.2) | 1 (16.7) | ||
| Reason of death | NA4 | ||||||||
| Myocardial infarction | 2 (2.3) | 2 (3.5) | 0 | 2 (5.3) | 0 | 0 | 0 | NA4 | |
| Respiratory/COPD | 3 (3.4) | 3 (5.3) | 0 | 3 (7.9) | 0 | 0 | 0 | ||
| Recurrence | 8 (9.2) | 2 (3.5) | 6 (20.0) | 0 | 2 (10.5) | 3 (12.5) | 3 (50.0) | ||
| Metachronous cancer | 4 (4.6) | 3 (5.3) | 1 (3.3) | 3 (7.9) | 0 | 1 (4.2) | 0 | ||
| Unknown | 2 (2.3) | 2 (3.5) | 0 | 2 (5.3) | 0 | 0 | 0 | ||
| Alive | 68 (78.2) | 45 (78.9) | 23 (76.7) | 28 (73.7) | 17 (89.5) | 20 (83.3) | 3 (50.0) | ||
| Adjuvant chemotherapy, n (%) | 23 (26.4) | 23 (26.4) | 23 (76.6) | NA | 0 | 0 | 19 (79.7) | 4 (66.6) | NA |
| Recurrence, n (%) | 7 (8.0) | 7 (8.0) | 7 (23.3) | NA | 0 | 0 | 4 (16.6) | 3 (50) | NA |
| 5-yr overall survival, n (%) | 68 (78.2) | 68 (78.2) | 23 (76.7) | 0.87511 | 28 (73.7) | 17 (89.5) | 20 (83.3) | 3 (50.0) | 0.14411 |
| 5-yr disease-free survival, n (%) | 76 (87.4) | 76 (87.4) | 23 (76.7) | 0.04911 | 38 (100) | 15 (78.9) | 20 (83.3) | 3 (50.0) | 0.00111 |
1p-value comparing stage I/II vs stage III; 2p-value for χ2 test; 3p-value for independent samples t-test; 4p-value not available due to extremely skewed distribution; 5p-value comparing four groups; 10p-value for ANOVA; 11p-value for log-rank test
SS1a, stage I (T1-2 N0 M0) and stage II (T3-4 N0 M0)
SS2b, stage III (any T N1-2 M0)
RS16, stage I/II, no occult tumor cells (OTC) in D1/D2 and D3 volumes
RS27, stage I/II, OTC in D1/D2 and/or D3 volumes. Number of OTC:18 isolated tumor cells (ITC) and 1 micrometastasis (MM)
RS38, stage III, lymph node metastases in D1/D2, with/without OTC in the D3 volumes. One patient had ITC in D3 volumes
RS49, stage III, lymph node metastases in D3, with/without OTC in D3 volumes. 3 patients had ITC, of which 1 had MM